focus -WSS

focus

author：Wikipedia 2025-09-29 16:36:06 - browse：27754

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

knowledge

WSS

Weight loss drugs should be covered by insurers, AMA says

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Medicare’s new pay boost for primary care is angering specialists

Experimental asthma app from Apple and Anthem shows promise

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Experimental asthma app from Apple and Anthem shows promise

focus

focus

focus

Hollywood unions extend contract negotiations for actors

Trump indictment: Who are the 'co

Hepatitis C has a cure — but many Americans still lack access to it

Breakthrough Alzheimer’s drugs are inaccessible in rural states

United colonoscopy coverage change 'may cost lives,' doctors say

Experimental asthma app from Apple and Anthem shows promise

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

At least 13 dead in Texas as scorching temps continue

After decades in use, heart stents finally beat placebo

focus

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

After decades in use, heart stents finally beat placebo

Sage hopes for a blockbuster in antidepressant now before FDA

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Today's health inequities arise from racist U.S. history, say experts

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

knowledge

Wikipedia

leisure time

hotspot